Tratamiento oncológico del angiosarcoma cutáneo. Revisión de la literatura
Palabras clave:
hemangiosarcoma, neoplasias cutáneas, quimioterapia, radioterapia.Resumen
El hemangiosarcoma cutáneo es una enfermedad maligna rara de origen vascular, y corresponde a menos del 1% de todas las malignidades y al 2% de todos los sarcomas de tejidos blandos. Su presentación usual es en el rostro y en la región del cuero cabelludo; al momento de diagnosticarse ya es una enfermedad avanzada. Afecta a menudo al anciano del género masculino y de raza blanca. El tratamiento oncológico se basa en la resección quirúrgica, la radioterapia y la quimioterapia, dado el alto riesgo tanto de recaída local como de diseminación hematológica con intención paliativa. Las tasas de control locorregional a 5 años son, aproximadamente, del 40% al 50%, las tasas de supervivencia libre de metástasis a distancia a 5 años están en el rango del 20% al 40%, y las tasas de supervivencia a 5 años se encuentran entre el 10% y el 30%.
Biografía del autor/a
Javier A. Quintero, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
Universidad del Bosque, Bogotá, D.C., Colombia
Jesús O. Sánchez, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
Néstor E. Llinás, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
Isabel C. Durango, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
Cristina Guarnizo, Instituto Nacional de Cancerología
Subdirección de Investigaciones, Vigilancia Epidemiológica, Promoción y Prevención, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
Juan A. Rubiano, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
Giovanna Rivas, Clínica, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
Fabio Grosso, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
Natalia Arango, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
Universidad del Bosque, Bogotá, D.C., Colombia
Javier Cuello, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia
Referencias bibliográficas
Mobini N. Cutaneous epithelioid angiosarcoma: a neoplasm with potential pitfalls in diagnosis. J Cutan Pathol. 2009;36:362-9.
https://doi.org/10.1111/j.1600-0560.2008.01052.x
Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer. 1987;59:1046-57.
https://doi.org/10.1002/1097-0142(19870301)59:5<1046::AID-CNCR2820590533>3.0.CO;2-6
Pawlik TM, Paulino AF, McGinn CJ, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer. 2003;98:1716-26.
https://doi.org/10.1002/cncr.11667
Morrison WH, Byers RM, Garden AS, et al. Cutaneous angiosarcoma of the head and neck: a therapeutic dilemma. Cancer. 1995;76:319-27.
https://doi.org/10.1002/1097-0142(19950715)76:2<319::AID-CNCR2820760224>3.0.CO;2-8
Sasaki R, Soejima T, Kishi K, et al. Angiosarcoma treated with radiotherapy: impact of tumor type and size on outcome. Int J Radiat Oncol Biol Phys. 2002;52:1032-40.
https://doi.org/10.1016/S0360-3016(01)02753-5
Alessi E, Sala F, Berti E. Angiosarcomas in lymphedematous limbs. Am J Dermatopathol. 1986;8:371-8.
https://doi.org/10.1097/00000372-198610000-00002
Stewart FW, Treves N. Classics in oncology: lymphan-giosarcoma in postmastectomy lymphedema: a report of six cases in elephantiasis chirurgica. CA Cancer J Clin. 1981;31:284-99.
https://doi.org/10.3322/canjclin.31.5.284
Marchal C, Weber B, de Lafontan B, et al. Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive cancer centers. Int J Radiat Oncol Biol Phys. 1999;44:113-9.
https://doi.org/10.1016/S0360-3016(98)00537-9
Yap J, Chuba PJ, Thomas R, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:1231-7.
https://doi.org/10.1016/S0360-3016(01)02799-7
Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11:241-7.
https://doi.org/10.1097/00130404-200505000-00011
Mark RJ, Poen JC, Tran LM, et al. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996;77:2400-6.
https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z
Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18:2030-6.
https://doi.org/10.1093/annonc/mdm381
Mendenhall WM, Mendenhall CM, Werning JW et al. Cutaneous angiosarcoma. Am J Clin Oncol. 2006;29:524-8.
https://doi.org/10.1097/01.coc.0000227544.01779.52
Penel N, Grosjean J, Robin YM, et al. Frequency of certain established risk factors in soft tissue sarcomas In adult: a prospective descriptive study of 658 cases. Sarcoma. 2008;2008:459386.
https://doi.org/10.1155/2008/459386
Costache M, Ene A, Simionescu O, et al. Histopathological diagnosis of cutaneous vascular sarcomas. Rom J Morphol Embryol. 2010;51:105-9.
Amo Y, Masuzawa M, Hamada Y, et al. Serum concentrations of vascular endothelial growth factor-D in angiosarcoma patients. Br J Dermatol. 2004;150:160-1.
https://doi.org/10.1111/j.1365-2133.2004.05751.x
Amo Y, Masuzawa M, Hamada Y, et al. Observations on angiopoietin 2 in patients with angiosarcoma. Br J Dermatol. 2004;150:1028-9.
https://doi.org/10.1111/j.1365-2133.2004.05932.x
Dim D, Ravi V, Tan J, et al. The actin-bundling motility protein fascin and vascular endothelial growth factor (VEGF) are universally over-expressed in human angiosarcoma. Proc Am Soc Clin Oncol. 2007;25:10068.
Itakura E, Yamamoto H, Oda Y, et al. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol. 2008;97:74-81.
https://doi.org/10.1002/jso.20766
Zietz C, Rumpler U, Sturzl M, et al. Inverse relation of Fasligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack. Am J Pathol. 2001;159:963-70.
https://doi.org/10.1016/S0002-9440(10)61772-5
Yamamoto T, Umeda T, Nishioka K. Immunohistological distribution of stem cell factor and kit receptor in angiosarcoma. Acta Derm Venereol. 2000;80:443-5.
https://doi.org/10.1080/000155500300012954
Isoda H, Imai M, Inagawa S, et al. Magnetic resonance imaging findings of angiosarcoma of the scalp. J Comput Assist Tomogr. 2005;29:858-62.
https://doi.org/10.1097/01.rct.0000183274.70422.0a
Edge SB, Byrd DR, Compton CC, et al., editors. AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010. pp. 291-8. 24. Naka N, Ohsawa M, Tomita Y, et al. Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases. J Surg Oncol. 1996;61:170-6.
https://doi.org/10.1002/(SICI)1096-9098(199603)61:3<170::AID-JSO2>3.0.CO;2-8
Abraham JA, Hornicek FJ, Kaufman AM, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007;14:1953-67.
https://doi.org/10.1245/s10434-006-9335-y
Casali PG, Jost L, Sleijfer S, et al. On behalf of the ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19:89-93.
https://doi.org/10.1093/annonc/mdn101
Girard C, Johnson WC, Graham JH. Cutaneous angiosarcoma. Cancer. 1970;26:868-83.
https://doi.org/10.1002/1097-0142(197010)26:4<868::AID-CNCR2820260421>3.0.CO;2-L
Wilson-Jones E. Malignant angioendothelioma of the skin. Br J Dermatol. 1964;76:21-39.
https://doi.org/10.1111/j.1365-2133.1964.tb13970.x
DeMartelaere SL, Roberts D, Burgess M, et al. Neoadjuvant chemotherapy-specific and overall treatment outcomes in patients with cutaneous angiosarcoma of the face with periorbital involvement. Head Neck. 2008;30:639-46.
https://doi.org/10.1002/hed.20757
Casper ES, Waltzman RJ, Schwartz GK, et al. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest. 1998;16:442-6.
https://doi.org/10.3109/07357909809011697
Fata F, O'Reilly E, Ilson D, et al. Placitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034-7.
https://doi.org/10.1002/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P
Verleysen A, Dewolf K, Geerts ML, et al. Angiosarcoma of the face and scalp. Eur J Dermatol. 2000;10:403-4.
Nagano T, Yamada Y, Ikeda T, et al. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer. 2007;110:648-51.
https://doi.org/10.1002/cncr.22822
Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26:5269-74.
https://doi.org/10.1200/JCO.2008.17.3146
Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005;104:361-6.
https://doi.org/10.1002/cncr.21140
Young RJ, Brown NJ, Reed MW, et al. Angiosarcoma Lancet Oncol. 2010;11:983-91.
https://doi.org/10.1016/S1470-2045(10)70023-1
AgulnikM,OkunoSH,VonMehrenM,etal.Anopen-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. J Clin Oncol. 2009;27(Suppl):10522.
Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133-40.
https://doi.org/10.1200/JCO.2008.20.4495
Ryan CW, von Mehren M, Rankin JC, et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. Proc Am Soc Clin Oncol 2008;26:10532.
https://doi.org/10.1200/jco.2008.26.15_suppl.10532
George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27:3154-60.
https://doi.org/10.1200/JCO.2008.20.9890
Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of Imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J Clin Oncol. 2009;27:3148-53.
https://doi.org/10.1200/JCO.2008.20.5054
Burns BT, Blakey SA, Harris WB. Complete response of metastatic angiosarcoma to liposomal doxorubicin and interferon-2a. Proc Am Soc Clin Oncol. 2002;21:2939.
Ohguri T, Imada H, Nomoto S, et al. Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy. Int J Radiat Oncol Biol Phys. 2005; 61:1446-53.
Cómo citar
Descargas
Descargas
Publicado
Número
Sección
Licencia
Todos los derechos reservados.
Estadísticas de artículo | |
---|---|
Vistas de resúmenes | |
Vistas de PDF | |
Descargas de PDF | |
Vistas de HTML | |
Otras vistas |